One third of ER+ breast tumors expressed high levels of PD-L2 protein in cancer cells, which correlated with shorter progression-free survival (PFS) and remained independently predictive of poor outcome after multivariable adjustment for common clinicopathological variables. This evidence concerns the gene PDCD1LG2 and breast neoplasm.